Clever Culture Systems (CC5) Q4 2025 earnings summary

Executive summary

• Fiscal year 2025 marked a pivotal turning point with the successful launch and routine use of APAS Independence at AstraZeneca, validating the technology in pharmaceutical manufacturing and securing Novo Nordisk for a group-wide evaluation.

• Five top-tier pharmaceutical companies, including AstraZeneca, Bristol-Myers Squibb, Thermo Fisher Pharma Services, Novo Nordisk, and one other, are deploying or evaluating APAS Independence, representing significant early-stage sales opportunities.

• Clinical market expansion continues with a third APAS Independence instrument installed at Health Services Laboratory in the UK.

• The company is expanding instrument capability with a major upgrade to support contact plate analysis, doubling the instrument's functionality.

• Commercialization efforts and a managed cost base have delivered financial stability, supported by a robust sales pipeline and growing recurring revenue.

Financial highlights

• Cash balance at 30 June 2025 was AUD 1.3 million (or $1.265 million), with committed or known cash inflows of at least AUD 3.8 million expected in the next two quarters.

• Net cash outflows for the quarter ended 30 June 2025 were AUD 0.95 million, mainly from operating and investing activities.

• Receipts from customers for the quarter totaled $888,000; year-to-date receipts were $4.65 million.

• Estimated $1.1 million R&D Tax Incentive receipt expected for FY25.

• 397 million listed options with an exercise price of AUD 0.008 expiring November 2025 could raise up to AUD 2.4 million (or $3.2 million) if fully exercised.

Outlook and guidance

• The remainder of 2025 is expected to see growth driven by expanding pharmaceutical customers and the launch of the contact plate application, enabling dual plate processing.

• Anticipated conversion of additional sales over the next six months to diversify the install base and support sustained growth.

• Participation in major pharmaceutical microbiology conferences in the second half of 2025 to showcase customer data and reinforce market leadership.